# A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer

Source: https://onco.cc/trials/nct04951635/  
OnCo record `nct04951635` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Aumolertinib in non-small-cell lung cancer and small-cell lung cancer, run by Jiangsu Hansoh Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer is a phase 3 interventional study registered as NCT04951635 by Jiangsu Hansoh Pharmaceutical Co., Ltd., with 150 participants planned, started 2021-03-18 and due to reach its primary completion in 2024-07-15. Interventions recorded: Almonertinib, Placebo Almonertinib. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04951635
- Phase: 3
- Setting: A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre Study of Almonertinib as Maintenance Therapy in Patients With Locally Advanced, Unresectable EGFR Mutation-positive Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based Chemoradiation Therapy
- Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Enrolled: 150

## Sources

- ClinicalTrials.gov NCT04951635: https://clinicaltrials.gov/study/NCT04951635

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Aumolertinib](https://onco.cc/drugs/aumolertinib/)

---
JSON: https://onco.cc/api/v1/entities/nct04951635.json